X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Orca-T is an investigational allogeneic T-cell immunotherapy being evaluated in clinical trials for the treatment of multiple hematologic malignancies, such as AML.
Lead Product(s): Allogeneic T-Cell Immunotherapy
Therapeutic Area: Oncology Product Name: Orca-T
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2024
Details:
Orca-Q is an investigational allogeneic cellular therapy consisting of a single infusion containing a proprietary composition of stem and immune cells derived from peripheral blood from either related or unrelated matched, unmatched or haploidentical donors.
Lead Product(s): Orca-Q
Therapeutic Area: Oncology Product Name: OrcaGraft
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
TregGraft (Orca-T) is an investigational high-precision allogeneic cellular therapy consisting of infusions containing regulatory T-cells, conventional T-cells and CD34+ stem cells derived from peripheral blood from either related or unrelated matched donors.
Lead Product(s): Orca-T
Therapeutic Area: Oncology Product Name: TregGraft
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2022
Details:
TregGraft (Orca-T) , an investigational, high-precision allogeneic cell therapy derived from stem and immune cells from either related or unrelated HLA-matched donors, is intended to safely replace a patient’s compromised blood and immune system with that from healthy donor.
Lead Product(s): Orca-T
Therapeutic Area: Oncology Product Name: TregGraft
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
Pooled data from 137 patients show Orca-T, an investigational high-precision allogeneic cellular therapy improved overall survival and reduced chronic graft versus host disease compared to standard of care.
Lead Product(s): Orca-T
Therapeutic Area: Oncology Product Name: TregGraft
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
Early multi-center results indicate that Orca-T, a novel approach to HSCT, improves time-to-engraftment, markedly reduces the incidence and severity of GvHD, and significantly improved GRFS at 1 year.
Lead Product(s): TregGraft
Therapeutic Area: Oncology Product Name: Orca-T
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2020
Details:
Preliminary data from the Phase I/II clinical trials of Orca-T will be presented at the 62nd American Society of Hematology Annual Meeting. Data provide insights into manufacturing efficiency, logistics and early clinical outcomes of Orca-T for patients with blood cancers.
Lead Product(s): TregGraft
Therapeutic Area: Oncology Product Name: Orca-T
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
Orca-T is an allogeneic, high-precision cell therapy for patients with blood cancers who are eligible for a hematopoietic stem cell transplant. Orca-T has received ODD from the FDA for enhancing cell engraftment in patients who qualify for a hematopoietic stem cell transplant.
Lead Product(s): TregGraft
Therapeutic Area: Oncology Product Name: Orca-T
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2020
Details:
The partnership promotes complementary scientific technologies to develop next generation cell-based therapies for patients with solid cancers.
Lead Product(s): T cell therapies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Lyell Immunopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 02, 2020
Details:
The financing will support the continued advancement of Orca Bio’s cell therapy pipeline and its novel manufacturing platform, which sorts blood with single-cell precision and a high level of purity and speed to create optimal therapeutic mixtures of immune and stem cells.
Lead Product(s): TRGFT-201
Therapeutic Area: Oncology Product Name: TRGFT-201
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Lightspeed Venture
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing June 17, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
